Stem Cell Therapy Companies

Top Industry Leaders in the Stem Cell Therapy Market

Latest Stem Cell Therapy Companies Update

• 
  July 2023: In July of 2023, biopharmaceutical startup Abeona Therapeutics announced that it has raised $25 million from a select group of current investors to forward development of its primary medicine, EB-101. The company intends to use the funds to be ready for the introduction of EB-101 and the filing of the BLA. EB-101 is an autologous, engineered cell therapy for the skin disorder recessive dystrophic epidermolysis bullosa. The company can submit a request for a priority review voucher (PRV) from the FDA after the BLA has been granted since the medicine treats a rare pediatric ailment.

• 
  August 2023: The FDA approved ANPD001, an investigational stem cell treatment developed by Aspen Neuroscience to restore damaged nerve cells in Parkinson's disease patients. The open-label Phase 1/2a trial is designed to examine the early effectiveness, safety, and dose-ranging tolerability of ANPD001 in patients with moderate to severe Parkinson's disease. More than a million individuals in the United States and 10 million people globally suffer from Parkinson's disease; FDA approval opens the door to a new treatment. Dopaminergic neurons are destroyed in Parkinson's disease, and ANPD001 is designed to restore them. There are three stages involved in the production of the stem cell treatment.

• 
  October 2023: In order to meet the growing demand for cell treatments throughout the world, Bayer AG announced in October 2023 that it would be constructing a Cell Therapy Launch Facility in Berkeley, California. BlueRock Therapeutics' bemdaneprocel (BRT-DA01) is an experimental cell therapy being studied for the treatment of Parkinson's disease. The $250 million (USD), 100,000 square foot facility will supply the material necessary for late-stage clinical studies and perhaps a commercial launch. It also has room for an extra production suite module to accommodate Bayer's expanding cell therapy range. Clinical-stage cell treatment firm BlueRock Therapeutics LP is a wholly-owned, separately managed subsidiary of Bayer AG.

• Seraxis, Inc. (Germany)


• ViaCyte, Inc. (US)


• Betalin Therapeutics Ltd (Israel)


• NextCell Pharma AB (US)


• Kadimastem (Israel)


• Vertex Pharmaceuticals (US)


• Fresenius Medical Care AG & Co. KGaA (Germany)


• Sernava Corp (Canada)


• Novo Nordisk A/S (Denmark)


• Generex Biotechnology (Canada)